SCHEMBL7166453

SCHEMBL7166453

Cc1ccc(S(=O)(=O)c2ccc3c(c2)c(CCN(C)C(=O)OC(C)(C)C)cn3C)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.42
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.38
GAA P10253 1/20 0.37
TP53 P04637 1/20 0.37
MAPT P10636 3/20 0.36
RXFP1 Q9HBX9 1/20 0.36
NQO2 P16083 1/20 0.35
MTNR1A P48039 1/20 0.35
MTNR1B P49286 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HPGD P15428 1/20 0.35
RECQL P46063 1/20 0.35
CDK2 P24941 1/20 0.35
HTR1D P28221 1/20 0.35
SPR P35270 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7163608 0.83 ALDH1A1 (0.36) HTR6KMT2AMEN1ALDH1A1GAA
SCHEMBL6577287 0.82 NQO2 (0.47) KMT2AMEN1GAATP53MAPT
SCHEMBL7167082 0.76 HTR6 (0.41) HTR6SPR
SCHEMBL6580203 0.76 GAA (0.40) HTR6KMT2AMEN1ALDH1A1LMNA
SCHEMBL6579474 0.76 ADRB2 (0.53) HTR6KMT2AMEN1GAATP53
Hydrochloric Acid SCHEMBL6577815 0.74 ADRB2 (0.52) HTR6KMT2AMEN1GAATP53
SCHEMBL7166243 0.74 HTR6 (0.41) HTR6SPR
SCHEMBL6579630 0.74 NQO2 (0.47) HTR6KMT2AMEN1MAPTNQO2
SCHEMBL7163717 0.74 HTR6 (0.43) HTR6KMT2AMEN1ALDH1A1GAA
SCHEMBL7170076 0.73 HTR6 (0.39) HTR6SPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6565829-B2 Psychological disorders; central nervous system disorders PHARMACIA & UPJOHN COMPANY 2003-05-20 US claimed
US-20030060498-A1 5-arylsulfonyl indoles useful for treating disease PHARMACIA & UPJOHN COMPANY 2003-03-27 US claimed
US-6565829-B2 Psychological disorders; central nervous system disorders PHARMACIA & UPJOHN COMPANY 2003-05-20 US disclosed
US-20030060498-A1 5-arylsulfonyl indoles useful for treating disease PHARMACIA & UPJOHN COMPANY 2003-03-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030060498-A1 5-arylsulfonyl indoles useful for treating disease IDO1, HTR5A, IDO2 HTR6 14/4885KMT2A 772/4885MEN1 1422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.